
FDA OKs Perioperative Pembrolizumab in HNSCC: Findings From KEYNOTE-689
Published: | Updated:
Ravindra Uppaluri, MD, PhD, discusses findings from the KEYNOTE-689 trial in adult patients with resectable, locally advanced head and neck squamous cell carcinoma.
